Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 14, 2026Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics

Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential

View Full Paper
Ask AI
Bookmark
Share

Authors

TVThanh Hoa VoEMEdel A. McNeelaOOOrla O’Donnovan

Discussion

Loading...

Member takes

Overview

This review highlights lncRNAs' implications in drug resistance in HER2-positive breast cancer, suggesting novel therapeutic targets.

Key Points

  • The aim is to synthesize evidence on lncRNA-mediated resistance mechanisms in HER2-positive breast cancer and explore translational opportunities.
  • Review of current evidence on lncRNA roles in resistance mechanisms.
  • Analysis of epigenetic, transcriptional, and post-transcriptional processes.
  • Discussion of lncRNAs as potential biomarkers and therapeutic targets.
  • Identified key lncRNAs involved in resistance mechanisms.
  • Emphasized potential of exosomal lncRNA profiling and circulating tumor DNA monitoring.
  • Outlined translational applications for lncRNAs in clinical settings.

Cite This Study

Vo et al. (2026) studied this question.

synapsesocial.com/papers/69b4adb518185d8a398017ddhttps://doi.org/10.32604/or.2026.075346
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of long non-coding RNAs in therapy resistance of cervical cancer and therapeutic potential2026 · 1 citations
  2. 2Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications2024 · 7 citations
  3. 3lncRNAs as Targetable Nodes of Oncogenic Networks Underlying Cancer Progression and Therapy Resistance2025
  4. 4lncRNAs as Targetable Nodes of Oncogenic Networks Underlying Cancer Progression and Therapy Resistance2025
  5. 5LncRNAs as regulators of chemoresistance and chemosensitivity in triple-negative breast cancer2026